Author

Tomotaka Shingaki

Observed names: Shingaki, Tomotaka, T Shingaki

ORCID: 0000-0003-1568-9763

Observed ORCID: 0000-0003-1568-9763

OpenAlex ID: A5041854551

Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

2025 · Takashi Kadowaki, Arihiro Kiyosue, et al. · The Lancet Diabetes & Endocrinology · 50

[Lymphocytic infundibulo-hypophysitis with diabetes insipidus as a new clinical entity: a case report and review of the literature].

1997 · K Miyagi, T Shingaki, et al. · PubMed · 21

Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes

2017 · Shizuka Kaneko, Tomonori Oura, et al. · Endocrine Journal · 20

PDF

Key factors for overcoming psychological insulin resistance: A qualitative study in Japanese people with type 2 diabetes

2022 · Kentaro Okazaki, Noriyuki Takahashi, et al. · Primary care diabetes · 10

PDF

Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study

2020 · Tomotaka Shingaki, Kentaro Taki, et al. · Current Medical Research and Opinion · 10

Real-world cross-sectional study evaluating patient characteristics, disease burden, and treatment approaches in people with obesity disease in Japan

2025 · Tomohiro Tanaka, Taisuke Kojima, et al. · Current Medical Research and Opinion · 8

PDF

Efficacy and safety of once‐weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT ‐2 trial

2025 · Toshimasa Yamauchi, Taro Asakura, et al. · Diabetes Obesity and Metabolism · 7

PDF

Successful Healthcare Provider Strategies to Overcome Psychological Insulin Resistance in Japanese Patients with Type 2 Diabetes

2019 · Kentaro Okazaki, Tomotaka Shingaki, et al. · Diabetes Therapy · 7

PDF

Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: a post-marketing safety study

2020 · Kentaro Taki, Momoha Koyanagi, et al. · Current Medical Research and Opinion · 6

Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT ‐J trial

2025 · Koutaro Yokote, Yasushi Fukushima, et al. · Diabetes Obesity and Metabolism · 5

PDF

2018 · Hiroshi Nishiyama, Tomotaka Shingaki, et al. · Diabetes Therapy · 5

PDF

Clinical and Humanistic Burden of Adult Obesity in Asia–Pacific: A Systematic Literature Review

2025 · Esther Artime, Sarah Zimner-Rapuch, et al. · Advances in Therapy · 3

PDF

Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT ‐1 Trial

2026 · Yasushi Ishigaki, Masamichi Yamada, et al. · Obesity · 1

PDF

Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial

2026 · Koutaro Yokote, Toshimasa Yamauchi, et al. · The Lancet Diabetes & Endocrinology

Changes in Abdominal Adiposity and Associations with Metabolic Health Markers Following Tirzepatide in Japanese Participants with Obesity Disease: Results from the SURMOUNT-J Study

2026 · Hironori Waki, Eiji Kaneyuki, et al. · Endocrine Practice

PDF

Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial

2026 · Takumi Kitamoto, Mihoko Yoshino, et al. · Figshare

Experience with Tirzepatide and Weight Management During and After a Clinical Trial in Japanese Patients with Obesity Disease: A Qualitative Study

2026 · Arihiro Kiyosue, Manaka Sato, et al. · Advances in Therapy

PDF

Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial

2026 · Takumi Kitamoto, Mihoko Yoshino, et al. · Current Medical Research and Opinion

Effect of Tirzepatide on Health‐Related Quality of Life in Japanese Patients With Obesity Disease: Patient‐Reported Outcomes From the SURMOUNT ‐J Study

2026 · Hiroaki Masuzaki, Hirotaka Nagashima, et al. · Diabetes Obesity and Metabolism

Medical costs attributable to obesity and obesity-related health disorders in a Japanese population using JMDC claims database

2026 · Kojima, Taisuke, Osaga, Satoshi, et al. · Figshare

Medical costs attributable to obesity and obesity-related health disorders in a Japanese population using JMDC claims database

2026 · Taisuke Kojima, Satoshi Osaga, et al. · Journal of Medical Economics

Author response for "Effect of tirzepatide on health-related quality of life in Japanese patients with obesity disease: Patient-reported outcomes from the SURMOUNT-J study"

2026 · Hiroaki Masuzaki, Hirotaka Nagashima, et al. · Publons reviews and discussion

Real-World Weight Loss Outcomes by Obesity Management Approaches in Japan: Descriptive Findings from the J-ORBIT Database Linked to Electronic Medical Records (J-ORBIT2)

2026 · Yushi Hirota, Seiji Nishikage, et al. · Diabetes Therapy

PDF

Author response for "Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial"

2025 · Koutaro Yokote, Yasushi Fukushima, et al. · Publons reviews and discussion

Works count: 27

Citation count: 153

H-index: 7

I10-index: 5